GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCryst Pharmaceuticals Inc (NAS:BCRX) » Definitions » Gross Margin %
中文

BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Gross Margin %

: 98.25% (As of Dec. 2023)
View and export this data going back to 1994. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. BioCryst Pharmaceuticals's Gross Profit for the three months ended in Dec. 2023 was $91.8 Mil. BioCryst Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $93.4 Mil. Therefore, BioCryst Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 98.25%.


The historical rank and industry rank for BioCryst Pharmaceuticals's Gross Margin % or its related term are showing as below:

BCRX' s Gross Margin % Range Over the Past 10 Years
Min: 89.76   Med: 95.73   Max: 99.1
Current: 98.59


During the past 13 years, the highest Gross Margin % of BioCryst Pharmaceuticals was 99.10%. The lowest was 89.76%. And the median was 95.73%.

BCRX's Gross Margin % is ranked better than
96.46% of 735 companies
in the Biotechnology industry
Industry Median: 60.01 vs BCRX: 98.59

BioCryst Pharmaceuticals had a gross margin of 98.25% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for BioCryst Pharmaceuticals was 0.80% per year.


BioCryst Pharmaceuticals Gross Margin % Historical Data

The historical data trend for BioCryst Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 91.60 90.59 95.38 97.57 98.59

BioCryst Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 96.86 98.64 98.85 98.69 98.25

Competitive Comparison

For the Biotechnology subindustry, BioCryst Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals Gross Margin % Distribution

For the Biotechnology industry and Healthcare sector, BioCryst Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Gross Margin % falls into.



BioCryst Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

BioCryst Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=326.8 / 331.412
=(Revenue - Cost of Goods Sold) / Revenue
=(331.412 - 4.661) / 331.412
=98.59 %

BioCryst Pharmaceuticals's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=91.8 / 93.401
=(Revenue - Cost of Goods Sold) / Revenue
=(93.401 - 1.637) / 93.401
=98.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


BioCryst Pharmaceuticals  (NAS:BCRX) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

BioCryst Pharmaceuticals had a gross margin of 98.25% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


BioCryst Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Executives
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Helen M. Thackray director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Jon P Stonehouse director, officer: CEO 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Charles K Gayer officer: Vice President and CCO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Michael L Jones officer: Exec Director, Finance - PAO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Alane P Barnes officer: VP, General Counsel & Corp Sec 1929 BRASSFIELD ROAD, RALEIGH NC 27614
Anthony Doyle officer: Chief Financial Officer 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Yarlagadda S Babu officer: VP Drug Discovery 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
George B Abercrombie director C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
William P Sheridan officer: SR VP - CMO 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Amy E Mckee director 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Lee Kenneth B Jr director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
Steven K Galson director C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703